The Karius test harnesses next-generation sequencing to detect fragments of cell-free DNA from bacteria, viruses, fungi and protozoa that may be circulating in a patient’s bloodstream.
Founded in 2008, Eiger BioPharmaceuticals is a late-stage biopharmaceutical company focused on developing and commercializing targeted therapies for rare diseases.
USA Mining 2025-26 pre-release is a snapshot capturing insights from over 70 executives and decision-makers across the value chain and from coast to coast, sharing not only how the industry is changing, but also where it is heading next.